Of note, while both PNPLA3 and TM6SF2 variants are widely acknowledged as promoting NAFLD-HCC, neither was independently significant of all the other risk factors in this single centre cohort. The gene discussed is TM6SF2; the disease is metabolic dysfunction-associated steatotic liver disease.